Content Library

Exclusive Speaker Interview: Shaperon

Seung-Yong Seong
CEO/Founder
Shaperon
Inflammasome Therapeutics Summit speaker faculty

Preview:

Can you explain your development programs?

We have five development programs under clinical or IND-enabling stages. We have chosen indications whose pathogenesis is closely linked to the activation of inflammasome and a broad spectrum of pro-inflammatory cytokines in order to maximize the benefit of our novel MoA...

Exclusive Speaker Interview: Ventus Therapeutics

Mike Crackower
Head of Research & Development
Ventus Therapeutics
Inflammasome Therapeutics Summit speaker faculty

Preview:

What do you see as the most compelling opportunities to create innovative medicines targeting the innate immune system?

The innate immune system is the body’s first line of defense against invading pathogens. However, it also plays a critical role in responding to cell stress and cellular damage to maintain cell and tissue homeostasis. Because of these critical roles, innate immune pathways are tightly regulated...

Event Highlights 2019

Inflammasome Therapeutics Summit
Post-Event Report 2019
Hanson Wade

Summary Of Key Findings From The Inaugural Inflammasome Therapeutics Summit | Boston 2019

The inaugural Inflamamsome Therapeutics Summit made its debut in Boston this October 29-31, 2019. The conference was a huge success with over 150 attendees in the room from over 70 organizations.

Over 3 days, expert speakers delivered thought-provoking sessions, covering the biology of the inflammasome, assessing preclinical animal models and benchmarking the specific diseases the inflammasome can target. This meeting provides delegates with valuable learning and networking opportunity for the inflammasome community. This report summarises some of the key findings from the event.

Exclusive Speaker Interview: Matt Cooper

Matt Cooper
Chief Executive Officer & Co-Founder
Inflazome
Inflammasome Therapeutics Summit speaker faculty

Preview:

What do you believe to be the biggest challenges that inflammasome developers are currently facing?

Proof of concept in the appropriate clinical indication(s). There are thousands of scientific papers describing animal model efficacy and target validation for inflammasomes. Together, they implicate a putative causal role for inflammasome activation in disease, but it is not known if these findings will translate to humans. Although blocking IL-1β has been validated in some human diseases, inhibiting NLRP3 may be different as it will also suppress downstream IL-18 and pyroptosis (lytic cell death) while leaving the biological activity of other inflammasome members intact to fight infection...